International Journal of Hematology

, Volume 93, Issue 5, pp 677–680

Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant

  • Yuval Tal
  • Guy Haber
  • Matan J. Cohen
  • Micci Phillips
  • Gail Amir
  • Dina Ben-Yehuda
  • Arie Ben-Yehuda
Case Report

Abstract

We present a case of a 52-year-old male who was evaluated due to anorexia, persistent diarrhea, weight loss, and liver enzyme elevations, with no hematologic laboratory abnormalities. Imaging modalities revealed several tissue lesions involving the pancreas, the right kidney, and an axillary lymph node. Diagnosis of Castleman disease was reached only due to the tissue obtained from the lymph node. Chemotherapy and immunosuppression led to a short remission. The patient underwent autologous stem cell transplantation, and has since been in remission. This case demonstrates the cryptogenic and chameleon-like nature of Castleman disease. Challenges in treating Castleman disease patients reflect current limitations and the need for a greater understanding of disease pathogenesis.

Keywords

Castleman disease Autologous stem cell transplantation 

Abbreviations

CD

Castleman’s disease

MCD

Multicentric Castleman’s disease

HIV

Human immunodeficiency virus

CT

Computed tomography

PET

Positron emission tomography

References

  1. 1.
    Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250(23):1001–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43(8):698–704.PubMedCrossRefGoogle Scholar
  3. 3.
    Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Klein WM, Rencic A, Munshi NC, Nousari CH. Multicentric plasma cell variant of Castleman’s disease with cutaneous involvement. J Cutan Pathol. 2004;31(6):448–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Miltenyi Z, Toth J, Gonda A, Tar I, Remenyik E, Illes A. Successful immunomodulatory therapy in Castleman disease with paraneoplastic Pemphigus Vulgaris. Pathol Oncol Res. 2008.Google Scholar
  6. 6.
    Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128(8):657–62.PubMedGoogle Scholar
  7. 7.
    Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003;82(12):766–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol. 2005;78(4):302–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.PubMedCrossRefGoogle Scholar
  10. 10.
    van Rhee F, Alikhan M, Munshi N, et al. Anti-IL6 antibody (ab) based strategies improve the management of HIV negative Castleman’s disease. Blood. 2004;104:897a.Google Scholar
  11. 11.
    Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease. Haematologica. 2007;92(6):857–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95(1):56–61.PubMedGoogle Scholar
  14. 14.
    Advani R, Warnke R, Rosenberg S. Treatment of multicentric Castleman’s disease complicated by the development of non-Hodgkin’s lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. Ann Oncol. 1999;10(10):1207–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Ogita M, Hoshino J, Sogawa Y, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68(3):171–6.PubMedGoogle Scholar
  16. 16.
    Repetto L, Jaiprakash MP, Selby PJ, Gusterson BA, Williams HJ, McElwain TJ. Aggressive angiofollicular lymph node hyperplasia (Castleman’s disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol. 1986;4(3):213–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004;104(10):3400–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Ganti AK, Pipinos I, Culcea E, Armitage JO, Tarantolo S. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol. 2005;79(3):206–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Halac M, Ergul N, Sager S, Demir A, Buyukpinarbasli N, Sonmezoglu K. PET/CT findings in a multicentric form of Castleman’s disease. Hell J Nucl Med. 2007;10(3):172–4.PubMedGoogle Scholar
  20. 20.
    Iagaru A, Mari C, Sam Gambhir S. Follicular dendritic sarcoma within a focus of Castleman’s disease. Serial FDG PET/CT in the follow up of recurrence with histopathologic confirmation. Rev Esp Med Nucl. 2007;26(1):40–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Pelosi E, Skanjeti A, Cistaro A, Arena V. Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman’s disease: a case report. J Med Case Rep. 2008;2:99.CrossRefGoogle Scholar
  22. 22.
    Ramos CD, Massumoto CM, Rosa MF, et al. Focal bone marrow involvement in multicentric Castleman disease demonstrated by FDG PET/CT. Clin Nucl Med. 2007;32(4):295–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Yuval Tal
    • 1
  • Guy Haber
    • 1
  • Matan J. Cohen
    • 1
  • Micci Phillips
    • 1
  • Gail Amir
    • 2
  • Dina Ben-Yehuda
    • 3
  • Arie Ben-Yehuda
    • 1
  1. 1.Department of Internal Medicine CHadassah-Hebrew University Medical CenterJerusalemIsrael
  2. 2.Department of PathologyHadassah-Hebrew University Medical CenterJerusalemIsrael
  3. 3.Department of HematologyHadassah-Hebrew University Medical CenterJerusalemIsrael

Personalised recommendations